Our three-part proprietary methodology, bioprognosis™ for kidney health, which forms the basis for kidneyintelX.dkd, starts with a patient blood test to measure biomarkers demonstrated to be highly prognostic for kidney disease progression and combines select clinical data features to generate an actionable result (Low, Moderate, or High).
one step in changing how we all can address under-recognized and undertreated chronic kidney disease in adult patients with type 2 diabetes.
1
Proprietary biomarkers
Biological factors that are clinically proven – in multiple studies – to be most prognostic for kidney disease progression (TNFR-1, TNFR-2, KIM-1).
Liu C, et al. J Am Soc Nephrol. 2022;33(9):1657-1672. doi:10.1681/ASN.2022010098
2
Select clinical features
3 select clinical variables from a patient’s health record (UACR, HbA1c, BUN) which are indicative of kidney/other key organ health or dysfunction.
3
Validated algorithm
Validated performance in multi-ethnic and multi-center cohorts with a test result that can help clinicians make medical decisions for today and tomorrow.
4
Yields a clear and actionable test report:
Individual patient risk result.
Low
Moderate
High
Only by starting at the earliest stages of diagnosed diabetic kidney disease – and by implementing the only FDA-approved test demonstrated to determine which adult patients with type 2 diabetes and chronic kidney disease (stages 1-3b) are at higher to lower risk for progressive decline in kidney function within five years – will clinicians and patients reap the greatest benefits from the treatment plan.
FREE EDUCATIONAL RESOURCES FOR YOUR STAFF AND PATIENTS
FREE EDUCATIONAL
RESOURCES FOR YOUR
STAFF AND PATIENTS
This valuable Guide and complementary Workbook provides simple, step-by-step guidance for how your patients can improve their kidney health in consultation with you and your staff.
This valuable Guide and complementary Workbook provides simple, step-by-step guidance for how your patients can improve their kidney health in consultation with you and your staff.
Prognosis, not diagnosis.
Current kidney function measurements can diagnose the presence of kidney disease at a single point in time. Our kidneyIntelX.dkd is designed to assess the likelihood that an adult patient with type 2 diabetes and with early-stage chronic kidney disease will progress over the next five years.
The test has been clinically validated to accurately assess the risk of progressive decline in kidney function. Here are some facts from the validation study:
- Patients identified with a “low” result experienced kidney function decline comparable to that of normal aging (in the absence of diabetes or CKD) and zero patients reached end-stage kidney disease within 5 years.
- Patients identified with a “moderate” result experienced kidney function decline at a ratio of 4x greater than those identified with a “low” result.
- Patients identified with a “high” result experienced kidney function decline at a ratio of 18x greater than those identified with a “low” result.
For detailed performance characteristics of kidneyintelX.dkd, see our Product Technical Sheet here.
To read the Study and find information about the rate of decline seen for the different levels of risk, click here.